Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Thursday, June 30, 2022.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2022 (2022-06-30): -1.73%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
EUDA Health Holdings Limited
Market Cap
$35.69M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$36.28M
Return on Invested Capital (ROIC)
-22.79%
TTM Avg
-490.24%
3Y Avg
-256.92%
5Y Avg
-224.31%
Market Cap
$36.51M
Return on Invested Capital (ROIC)
-171.36%
TTM Avg
-234.34%
3Y Avg
-204.54%
5Y Avg
-189.00%
Market Cap
$35.57M
Return on Invested Capital (ROIC)
-89.44%
TTM Avg
-27.62%
3Y Avg
-11.28%
5Y Avg
-9.71%
Market Cap
$36.70M
Return on Invested Capital (ROIC)
-166.02%
TTM Avg
-208.81%
3Y Avg
-185.70%
5Y Avg
-165.34%
Market Cap
$35.50M
Return on Invested Capital (ROIC)
-164.58%
TTM Avg
-155.30%
3Y Avg
-94.59%
5Y Avg
-73.98%
Market Cap
$34.50M
Return on Invested Capital (ROIC)
-52.61%
TTM Avg
-25.54%
3Y Avg
-42.13%
5Y Avg
-36.31%
Market Cap
$37.89M
Return on Invested Capital (ROIC)
12.67%
TTM Avg
5.06%
3Y Avg
-12.78%
5Y Avg
-16.11%
Market Cap
$37.81M
Return on Invested Capital (ROIC)
-32.18%
TTM Avg
-103.25%
3Y Avg
-133.41%
5Y Avg
-116.42%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| EUDA Health Holdings Limited (EUDA) | $35.69M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.28M | -22.79% | -490.24% | -256.92% | -224.31% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.51M | -171.36% | -234.34% | -204.54% | -189.00% |
| DocGo Inc. (DCGO)vs › | $35.57M | -89.44% | -27.62% | -11.28% | -9.71% |
| Edesa Biotech, Inc. (EDSA)vs › | $36.70M | -166.02% | -208.81% | -185.70% | -165.34% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.50M | -164.58% | -155.30% | -94.59% | -73.98% |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.50M | -52.61% | -25.54% | -42.13% | -36.31% |
| Nephros, Inc. (NEPH)vs › | $37.89M | 12.67% | 5.06% | -12.78% | -16.11% |
| Incannex Healthcare Limited (IXHL)vs › | $37.81M | -32.18% | -103.25% | -133.41% | -116.42% |
| Elutia Inc (ELUT)vs › | $34.48M | -79.27% | -43.87% | -333.47% | -212.56% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2022-06-30 | -1.73% |
| 2022-03-31 | -0.23% |
| 2021-12-31 | -26.97% |
